Tesofensine vs Retatrutide

Tesofensine wins for rapid appetite suppression, stimulant-like focus without classic jitter, and as a stall-breaker for users already adapted to GLP-1s. Its oral dosing and cutting legacy make it a strong pick where weekly injections aren't preferred or where a monoaminergic approach is desired.

Retatrutide wins for superior long-term fat loss (up to 24% in trials), body recomposition (visceral and liver fat hits), and convenience with true once-weekly protocols. Its triple-agonist mechanism attacks weight loss from multiple metabolic angles and typically yields greater absolute results, especially for sustained aggressive cuts.

Pick Tesofensine if:

• A research model requires appetite suppression with preserved focus and low stimulation;
• Rapid interruption of diet fatigue or food noise is needed without weekly injections;
• The protocol is GLP-1 tolerant or adapted but hunger returns (GLP-1 stall-breaker scenario);
• Cardiovascular status is well-managed and stimulant exposure is not problematic;
• Sourcing and handling oral compounds is preferred over peptides.

Pick Retatrutide if:

• The goal is maximum fat loss or body recomposition, especially with a focus on visceral adiposity and liver fat;
• Once-weekly injection fits the protocol better for compliance and scheduling;
• The model needs both appetite suppression and increased energy expenditure, with minimal off-target CNS stimulation;
• Stacking with and preserving lean mass during aggressive caloric deficit is a priority;
• Peptide sourcing and handling are not a barrier.